Objectives A continuous intervention based on healthcare management agreements was associated in our hospital with an increase in the absolute number of spontaneous reporting of adverse drug reactions (ADRs), and also with an increase in the number of reports of serious or unexpected ADRs and ADRs associated with new drugs. The objective was to analyse the effect of this intervention on the features of ADRs spontaneously reported in a hospital, the drugs involved and the number of signals identified.
Methods A longitudinal study with two periods, the 1st period without intervention from 1998 to 2002 and the 2nd period with intervention from 2003 to 2005, was carried out in a tertiary teaching hospital. Changes between the two periods with regard to the following variables were analysed: the patients' characteristics, such as gender and age; the reported ADRs, and the medical assistance required; the suspected drugs involved in the ADRs; the main signals identified. Results Gender and age distribution of patients described in the spontaneous reports were no different in the two periods. During the second period, spontaneously reported cases requiring hospital admission and those occurring in hospital increased (236 from 2 in the first period and 277 from 99 in the first period respectively) and cases from outpatient hospital consultations began to be reported (13.9% of reports). The spontaneous reporting on all kinds of ADRs and drugs increased during the second period. Cutaneous reactions were the most frequently spontaneously reported ADRs in both periods followed by cardiovascular and neurological reactions in the first period, and haematological and gastrointestinal reactions in the second one. However, during the second period the higher increase was for endocrinological, urinary and hepatic reactions. Systemic antibiotics, anti-thrombotics and cardiac therapy drugs were the most common therapeutic subgroups reported to be suspected drugs in both periods, but in the second period the proportion of immunostimulants, beta blocking agents, immunosuppressants and psychoanaleptics increased. No signals were recognised during the first period; however, two signals and one additional safety concern were identified during the second. Conclusion An intervention based on healthcare management agreements, was associated with an important increase in spontaneous reporting of ADRs by hospital physicians and also with a change in terms of the type of ADRs identified affecting different organs or systems, and the
Introduction
The spontaneous reporting system is currently the cornerstone of post-marketing signal detection in pharmacovigilance [1, 2] . Detection of adverse drug reactions (ADRs) in hospitals is important because serious events may be identified, novel drugs are commonly used, new and unexpected ADRs may be detected early on and cases are usually well-documented with high quality information. Nevertheless, spontaneous reporting has been scarcely used as a method of ADR detection in hospitals and under-reporting is a major flaw [3] [4] [5] , as it is in the primary health care setting [6] .
Several interventions (educational or others) aimed at solving this major problem have been proposed and the effectiveness of some of them has been evaluated in a number of studies [5, [7] [8] [9] [10] [11] [12] . In this sense, we have previously reported that an intervention based on healthcare management agreements with economic incentives and educational activities was associated with a quantitative and qualitative improvement of spontaneous reporting of ADRs by hospital physicians [13] . Not only did the absolute number of spontaneous reports increase, but so did the number of reports of serious or unexpected ADRs and ADRs associated with new drugs.
The pattern of adverse drug reactions notified by spontaneous reporting in hospitals has been described in a few studies [14] [15] [16] [17] [18] [19] . Furthermore, there are no studies assessing whether the improvement in reporting in the hospital setting allows a more efficient detection of new drug safety issues or whether it facilitates signal identification. The usefulness of an increase in spontaneous reporting depends on the increase in the number of meaningful reports that help to raise concerns [20] . Therefore, the aim of this study was to analyse the effect of the spontaneous reporting increase after an intervention in the hospital on the features of the ADRs reported, the drugs involved and the signals identified.
Materials and methods
A time series analysis was carried out at Vall d'Hebron University Hospital (Barcelona, Spain) from 1998 to 2005 in order to assess the effectiveness of a continuous multifaceted intervention for improving spontaneous reporting of ADRs by hospital physicians to the Pharmacovigilance Programme (PhVP) of the hospital. The intervention was based on healthcare management agreements between hospital managers and clinical services, and was initiated in 2003. A framework agreement between hospital managers and physicians included different commitments linked to economic incentives. One of the objectives for physicians was to increase their participation in the PhVP, increasing the number of spontaneous ADR reports. This objective was integrated into other clinical objectives at three levels:
1. Institution or whole hospital 2. Clinical department or clinical team 3. Physician
The financial incentive obtained was variable according to the objectives achieved, and was approximately 5-7% of the physician's salary. The size of the financial payment for ADR reporting accounted for less than 10% of the total of agreed incentives and was, on average, less than 1% of the physician's salary. In each clinical service, an initial meeting between physicians and the hospital pharmacovigilance team was held. In this first meeting, the hospital's pharmacovigilance activities, the aim of spontaneous ADR reporting and how to report ADRs, were presented. In addition to reinforcement, twice-yearly educational meetings were held in each clinical service, offering information about pharmacovigilance and emphasising the priorities for spontaneously reporting ADRs (serious ADRs, unexpected ADRs and those ADRs associated with new drugs). These meetings lasted 45-60 min, and consisted of a brief explanation of the number and main characteristics of ADRs detected in the whole hospital and in the specific clinical service. Signals identified by the PhVP and news about ADRs released by regulatory agencies were also commented on. Finally, reminder cards with the telephone number of the pharmacovigilance team and a list of the most important ADRs to be reported on (serious, unexpected and those associated with new drugs) were distributed to the hospital wards.
Changes between the two periods of study (the first period without intervention from 1998 to 2002 and the second period with intervention from 2003 to 2005) in the total number of spontaneous reports of ADRs, and in the number of serious reports, reports of unexpected ADRs and reports of ADRs related to recently marketed drugs were therein presented [13] .
In this paper, changes between the two periods in the following variables of the longitudinal study have been analysed:
1. The patients' characteristics, such as gender and age 2. The ADRs reported 3. The suspected drugs involved in the ADRs, including those recently marketed 4. The most frequent drug-ADR associations and the main signals identified
The ADRs were classified in organ system categories according to the World Health Organisation terminology (WHOART-WHO Adverse Reaction Terminology). The suspected drugs were grouped in therapeutic classes according to the Anatomical Therapeutic Chemical classification system. The seriousness of the cases was classified according to the European Union's criteria and cases were considered serious (ADRs that result in death, are lifethreatening, require hospitalisation or prolongation of existing hospitalisation, result in persistent or significant disability or incapacity, are a congenital anomaly or birth defect, or are important medical events) or non-serious (the remaining cases) [21] . Its outcome was classified into recovery, permanent sequelae, death or unknown. According to the medical attention required, the cases were classified into those requiring hospital admission, inhospital cases, cases requiring attention at the emergency room, and cases from the outpatient department. Previous knowledge of the ADRs was classified according to the Spanish Pharmacovigilance System's (SPhVS) causality algorithm in well-known ADRs, known from anecdotal reports, or unknown [22] . New drugs were defined as those marketed for less than 5 years at the time when the ADRs began.
Regarding statistical analysis, the spontaneous reports of ADRs during the two periods studied were analysed separately. Descriptive analysis of continuous variables was performed by means of median and range, and statistical differences were assessed by means of the Mann-Whitney test. Categorical variables were described using percentages; statistical differences were assessed by means of the Chi-squared test. Significance was set at a level of 0.05, two-tailed. The statistical analysis was performed using the SPSS version 15.0 statistical package (SPSS. Chicago, IL, USA).
Results

Number of spontaneous reports of adverse drug reactions
Of the total number of cases of ADRs identified by the PhVP, the proportion of spontaneous ADR reports increased from 29.5% (n=200) during the first period to 71.5% (n=631) during the second period. More details about this increase were presented in the previous paper [13] .
Patients' characteristics
Gender and age distribution of patients described in the spontaneous reports were no different between the two periods. The female-to-male ratio in the spontaneous reports from the first period was 1.08 (104 women and 96 men); it was 0.96 in the second one (310 women and 321 men; p=0.516). Median age (minimum-maximum) was 64 (14-94) for patients described in both periods (p=0.150).
Medical attention required
Most patients reported during the first period either required medical attention at the emergency room without hospital admission (99; 49.5%) or were in-hospital cases (99; 49.5%). The 2 remaining patients (1%) required hospital admission.
The number of patients requiring only medical attention at the emergency room decreased during the second period (30; 4.8%). In-hospital cases slightly decreased in relative terms, although the absolute number of reports increased (277; 43.9%). Conversely, the number of patients requiring hospital admission increased both in relative and in absolute terms (236; 37.4%). On the other hand, patients from the outpatient department not requiring attention at the emergency room or hospital admission began to be reported during the second period, accounting for 13.9% (88) of the overall reports received at the end of this period (p<0.001).
Seriousness and outcome
In the second period, the proportion of serious cases almost doubled (63.1% vs 32.5%) and the number of serious cases increased by more than 6-fold (398 vs 65; p<0.001).
The most frequently reported outcome in both periods was recovery (70% in the first one and 74.2% in the second one). Two patients in the first period and 16 in the second period recovered with sequelae. There were 9 fatalities during the first period and 15 in the second one. The adverse reactions and drugs involved in these fatalities are presented below in the section Drug-reaction associations. Finally, the outcome was unknown in 49 patients in the first period and 132 in the second one (p=0.153).
Adverse reactions
Overall, 220 adverse reactions were described in the 200 first-period spontaneous reports. Cutaneous reactions occurred most frequently, followed by cardiovascular and neurological reactions. In the 631 second-period spontaneous reports, 694 adverse reactions were described. Cutaneous reactions occurred most frequent in this period as well, followed by haematological and gastrointestinal reactions (Table 1) . However, during the second period the frequency of endocrinological, urinary and hepatic reactions increased (3.7% vs 0.5%, 4.6% vs 1.8% and 9.2% vs 5.5% respectively).
The most commonly reported individual adverse reactions (with a frequency≥3% of reports) during the first period were urticaria, angioedema, bronchospasm, hypotension and haematoma. In the second period, individual reactions described in≥3% of reports were rash and erythematous rash (Table 2) . During the second period the frequency of hyperthyroidism, thrombocytopaenia and gastrointestinal haemorrhage increased by 4.3-and more than 2-fold respectively.
Suspected drugs
Two hundred and eighty-five and 877 suspected pharmacological exposures were contained in the reports in the first and the second period respectively. In both periods, the most common therapeutic subgroups were systemic antibiotics, anti-thrombotics and cardiac therapy. These three groups accounted for 38.2% and 30.3% of the total suspected pharmacological exposures in each period respectively (Table 3) . Regarding the remaining therapeutic subgroups, the greatest changes between periods were the increase in the proportion of immunostimulants, beta blocking agents, immunosuppressants and psychoanaleptics, and the decrease in the proportion of systemic antihistamines during the second period.
The drugs with the highest number of suspected exposures were amiodarone, amoxicillin-clavulanic acid, metamizole, and enoxaparin in both periods (Table 4) .
Some drugs with no suspected exposures during the first period appeared during the second one (i.e. ceftriaxone, methotrexate and tacrolimus). Additionally, a 9-fold increase was seen in the number of suspected exposures to ibuprofen, azithromycin and fluoxetine during the second period. In both study periods, around 10% of suspected pharmacological exposures concerned recently marketed drugs. Nevertheless, both the overall number of suspected pharmacological exposures and the number of different drugs increased in the second period (97 vs 28, and 50 vs 19 respectively). The new drugs with the highest number of suspected exposures were clopidogrel, levofloxacin and nevirapine (three exposures each) in the first period, and linezolid (eight exposures), tiotropium bromide, glatiramer acetate, oxcarbazepine, tenofovir and voriconazole (five exposures each) in the second one.
Drug-reaction associations
In the first period, the most frequently reported drugreaction associations were haemoperitoneum, retroperitoneal Only adverse reactions present in at least five reports from any period are displayed haemorrhage or muscular haematoma due to enoxaparin (11 cases, 5.5% of reports). In the second period, they were hepatotoxicity induced by amoxicillin-clavulanic acid and hyperthyroidism due to amiodarone (14 cases and 2.2% of reports each; Table 5 ). Three out of nine fatal reports from the first period were cases of haemorrhagic reactions in patients treated with enoxaparin (2 with retroperitoneal haemorrhages and 1 with gastrointestinal bleeding), 3 were cases of cardiovascular reactions (myocardial infarction after terbutaline treatment, salbutamol and levofloxacin-induced torsade de pointes, and cardiac arrest in a patient treated with levomepromazine and carbamazepine) and the remaining three reports described adverse reactions related to other systems. The most frequent reactions in the 15 fatalities reported during the second period were also haemorrhagic events (7 patients). There were 4 patients with intracranial haemorrhage (3 of them with tenecteplase, enoxaparin and acetylsalicylic acid, and 1 with drotrecogin alpha and enoxaparin), 1 with enoxaparin-induced retroperitoneal haemorrhage, 1 with intra-abdominal haemorrhage due to enoxaparin, acenocoumarol and acetylsalicylic acid, and 1 with acetylsalicylic acid-induced gastrointestinal haemorrhage. Of the 8 remaining patients, 3 had toxic epidermal necrolysis and the other described reactions related to other systems.
Previous knowledge/signals identified
The absolute number of previously unknown or poorly known drug-reaction associations had a 4-fold increase in No signals were identified during the first period. In the second one, two serious and previously unknown or poorly known drug-reaction associations were considered signals that required the adoption of regulatory measures by the Spanish Agency for Medicines and Medical Devices (AEMPS). The first signal was pseudoproteinuria induced by gelatine succinate infusion. A warning regarding this problem was added in the summary of product characteristics [23] and a "Dear Dr letter" was sent to Spanish nephrologists and to the National Transplant Organisation. The second signal was veralipride withdrawal syndrome; it required a risk-benefit assessment of the use of this orthopramide in the treatment of menopausal hot flushes and, as a result, the AEMPS withdrew this drug from the market [24] . Afterwards, the EMEA also recommended the withdrawal of this drug from the European market [25] .
Additionally, the fatal case of cerebral haemorrhage due to drotrecogin alfa (activated), which occurred in a patient who had recently undergone surgery, led to a review of the safety data of this drug in the surgical population. As a result, the AEMPS proposed changes in the authorised conditions of use of drotrecogin alfa (activated) at the EMEA level. Those proposals contributed to updating the authorised conditions of use and contraindications for this drug [26] .
Discussion
To our knowledge, our study has been the first one to assess the effect of a specific intervention on the features of ADRs spontaneously reported in a hospital setting, the drugs involved and the number of signals identified. It has shown that the improvement in spontaneous reporting of ADRs achieved following an intervention based on educational activities and economic incentives allowed us to detect some safety problems and to identify several signals. It is noteworthy that the reporting of all kinds of adverse reactions and drugs increased.
The traditional methods and systems used to detect ADRs in hospitals have been spontaneous reporting, intensive surveillance of hospital admissions and, more recently, computer-assisted approaches using routine data from hospital information systems [3] . Different methods identify different types of ADRs and drugs. Moreover, the type of suspected drugs, their rank order and the types of ADRs identified vary widely among studies. In studies that only or predominantly included ADR-related hospitalisations, nonsteroidal anti-inflammatory drugs causing gastrointestinal bleeding play a major role, followed by cardiovascular drugs and drugs acting on the central nervous system. In contrast, anti-bacterial/anti-infectives very often cause ADRs in hospitalised patients (mainly allergic reactions), as do opioids, cardiovascular drugs and anti-coagulants [3] . In our study the most frequently reported ADRs were similar in both periods, although some types of ADRs that were hardly reported in the first period increased in the second one. Cutaneous reactions were the most frequently reported ADRs in both periods: other ADRs commonly reported during both periods were cardiovascular, haematological, neurological and gastrointestinal reactions. Nevertheless, a high increase in endocrinological, urinary and hepatic reactions was observed in the second period. There are no other published studies comparing the effect of an intervention on the organ system categories of reactions spontaneously reported in a hospital. A few studies have reported the pattern of spontaneously reported ADRs in hospitals [16-19, 27, 28] . As in ours, in the majority of these studies dermatological reactions were most frequently identified [17] [18] [19] 27] and skin rash was the most commonly reported reaction [17, 18] . Other ADRs such as neurological, gastrointestinal and haematological reactions were also frequently reported. However, it is interesting to note that, in contrast to our study, endocrinological and urinary reactions were rarely reported in others. In our opinion, the intervention could be responsible for the increase in the reporting of these ADRs in the second period. Further studies should be carried out to analyse the effect of different interventions on the features of the spontaneously reported ADRs.
The majority of therapeutic subgroups of suspected drugs increased during the intervention. Systemic antibiotics, anti-thrombotics and cardiac therapy drugs were the most commonly involved therapeutic subgroups in the spontaneous reports in both periods. These therapeutic subgroups were also frequently reported in other studies that assessed the drugs involved in spontaneously reported ADRs in hospitals [18, 19, 27] . In our study, the greatest changes between periods were the increase in the proportion of immunostimulants, immunosuppressants and psychoanaleptics. In addition, anti-neoplastics, a therapeutic subgroup highly reported in other studies [17, 19, 27] , also increased during the intervention. The therapeutic subgroups most commonly involved in the spontaneously reported ADRs were drugs frequently used in the hospital setting. Nevertheless, taking into account the differences in the pattern of suspected drugs in the two periods, it is likely that the intervention allowed us to identify during the second period some suspected drugs involved in ADRs infrequently reported in the first one. It would be interesting to investigate the effect of other interventions on the type of suspected drugs in spontaneously reported ADRs.
Furthermore, the absolute number of spontaneous reports of any origin increased during the second period, except for those from emergencies. It is worth noting that spontaneous reports from the outpatient hospital consultations began to be reported during the second period. The effect of the intervention was evident, since the physicians had been informed in the educational meetings that they could report ADRs from every assistance setting. Unexpectedly, spontaneous reporting of ADRs requiring only medical attention at the emergency room did not increase in spite of the intervention. The reason for that is unknown, although high attendance pressure, especially in this area, lack of time and other clinical priorities have been argued as potential obstacles to the spontaneous reporting of ADRs by the doctors at our hospital [5] . Therefore, in the emergency area some other specific strategies aimed at increasing spontaneous reporting should be planned.
One of the main objectives of spontaneous reporting of ADRs is to detect drug safety concerns related to new drugs. Surprisingly, the novelty of suspected drugs has not been analysed in published studies on spontaneous reporting in hospitals. In our study we observed that during the intervention the number of suspected pharmacological exposures to recently marketed drugs and the number of serious cases, including those with a fatal outcome, increased. It is noteworthy that one of the signals identified referred to a serious reaction to a recently marketed drug and arose through the reporting of a fatal case (i.e. intracranial haemorrhage associated with drotrecogin alfa (activated)).
The majority of drug-reaction associations spontaneously reported in both periods of the study were well-known reactions related to old drugs (i.e. haemorrhage due to enoxaparin, hepatotoxicity due to amoxicillin-clavulanic acid and hyperthyroidism due to amiodarone). However, the reporting of known ADRs can help to identify local problems related to the use of specific drugs. For example, in our hospital haemorrhages related to low molecular weight heparins led to an analysis of severe cases in order to identify possible risk factors. On the other hand, two previously unknown reactions associated with old drugs that were reported in the second period led to the withdrawal of the market of one drug and an update of the summary of the product characteristics in the other one. This point is interesting because it shows that even old drugs must be kept under surveillance through their entire life-span to detect some possible previously unknown reactions.
Obviously our study has some limitations. First of all, it was carried out in only one hospital with specific characteristics (a teaching tertiary hospital; the biggest one in our geographical area). Additionally, the Catalan Centre of the Spanish Pharmacovigilance System is located in the hospital. Therefore, our findings could not be generalised to other hospitals. Second, since our study was a time series study without a control group, we cannot rule out the influence of other factors in the observed results. Nevertheless, the number of the spontaneous ADRs reported by the other Catalan hospital to the Pharmacovigilance Regional Centre during the two study periods did not increase. Third, the number of signals identified was low and we cannot confirm the effect of intervention on its detection. Fourth, we did not collect information on the category of physicians, medical speciality and other characteristics of the reporters that might have influenced the results. In spite of all these limitations, our study generates new information on the effect of a specific intervention on the features of the spontaneously reported ADRs, the drugs involved and the signals identified. On the one hand, this confirms the usefulness of the implementation of these types of strategies to improve reporting of ADRs in hospitals. On the other hand, these results can be and even should be used as an argument when stimulating the spontaneous reporting by healthcare professionals by means of supporting evidence of the usefulness of pharmacovigilance activities.
In conclusion, an intervention based on educational activities and economic incentives led not only to a quantitative improvement in spontaneous reporting of ADRs by hospital physicians, but also to a qualitative improvement in terms of seriousness of reactions identified affecting different organs or systems, and the type of drugs involved, including those most recently marketed. Moreover, a number of signals were generated during the intervention and they contributed to the adoption of decisions by the regulatory authorities on either the withdrawal of drugs from the market or changes in the information contained in the summary of product characteristics of some drugs. Future studies should analyse the effect of other types of intervention on spontaneous reporting of ADRs in hospitals, the number of identified signals and the quickness of their recognition.
